SAN CARLOS, Calif., Aug. 29, 2022 /PRNewswire/ — Galaxy Medical today announced that it received the CE Mark for its CENTAURI Pulsed Electric Field (PEF) System and launched its commercial program. The approval allows the company to market the system for the treatment of paroxysmal atrial fibrillation (AF) in the European Union […]
Author: Ken Dropiewski
New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new […]
Medtronic Extravascular ICD meets global pivotal clinical trial’s safety and effectiveness endpoints
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA, Spain, Aug. 28, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead […]
Vascular Therapies Initiates Enrollment in ACCESS 2 Clinical Trial
– ACCESS 2 is a randomized clinical trial evaluating Sirogen for improving hemodialysis AV Fistula outcomes – CRESSKILL, N.J., Aug. 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the first patient in the ACCESS 2 […]
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular […]
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people August 27, 2022 10:36 AM Eastern […]
Shape Memory Medical Completes Enrollment in the AAA-SHAPE Early Feasibility Study
SANTA CLARA, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., developer of custom, proprietary shape memory polymers for the peripheral and neurovascular markets, announced the completion of patient enrollment in AAA-SHAPE, the Company’s prospective, multicenter early feasibility safety study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm (AAA) sac management […]
New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)
Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1,2,3 Latest findings presented at the European Society of Cardiology (ESC) Congress 2022 add to the wealth of edoxaban data reinforcing its safety and […]
Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll up […]



